Argos Therapeutics Inc., today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy, or treatment to shrink a tumor before surgery, in patients with localized renal-cell carcinoma. The study is being conducted at Roswell Park Cancer Institute and is designed to enroll a maximum of 10 patients who will be treated with AGS-003 before nephrectomy in order to assess immune-system response and tumor effects.